Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.39 |
| ▸ | HRH2 | P25021 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CCL5 | P13501 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094069 | 0.91 | GPR119 (0.43) | HRH1HRH2HRH3GPR119 | |
| SCHEMBL6095806 | 0.89 | HRH1 (0.40) | HRH1HRH2HRH3HTR7GPR119 | |
| SCHEMBL5965757 | 0.87 | HRH2 (0.36) | HRH1HRH2GPR119TRPV4CYP19A1 | |
| SCHEMBL6093051 | 0.85 | HRH1 (0.49) | HRH1HRH2HRH3HTR7HTR1A | |
| SCHEMBL6093467 | 0.83 | HRH2 (0.37) | HRH1HRH2HRH3GPR119USP30 | |
| SCHEMBL7248406 | 0.83 | HRH2 (0.37) | HRH1HRH2HRH3HTR7TRPV4 | |
| SCHEMBL6096890 | 0.82 | KCNA5 (0.46) | HRH1HRH2HRH3GPR119ALDH1A1 | |
| SCHEMBL6096906 | 0.82 | HRH1 (0.46) | HRH1HRH2HRH3HTR7CYP19A1 | |
| SCHEMBL6095400 | 0.81 | HTR7 (0.42) | HRH1HRH2HRH3HTR7CCL5 | |
| SCHEMBL2956811 | 0.81 | GPR119 (0.41) | HRH1HRH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | HRH1 2707/4885HRH2 2122/4885HRH3 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.